|Table of Contents|

Screening study for prostate cancer serum biomarkers based on iTRAQ proteomic technology

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
18-21
Research Field:
Publishing date:

Info

Title:
Screening study for prostate cancer serum biomarkers based on iTRAQ proteomic technology
Author(s):
Zhang Mo1; Chen Lizhu2; Yang Zeyu2; Yin Bo1; Song Yongsheng1
1.Department of Urology;2.Department of Ultrasound，Shengjing Hospital，China Medical University，Liaoning Shenyang 110004，China.
Keywords:
isobaric tag for relative and absolute quantitation; prostate cancer; proteomics; serum biomarker
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2018.01.005
Abstract:
Objective：To screen the differentially expressed serum proteins in patients with prostate cancer (PCa) and benign prostatic disease using isobaric tag for relative and absolute quantitation (iTRAQ) technology.Methods：Serum samples were collected from 4 groups of patients：benign prostatic hyperplasia (BPH) (n=10)，high grade prostatic intraepithelial neoplasia (HGPIN) (n=10)，localized PCa (n=10) and metastatic PCa (n=10).Equal volumes of serum from 10 patients within the same group were mixed.Then iTRAQ proteomic approach was used to identify and quantify the proteins differentially expressed in these groups.Results：A total of 825 serum proteins were finally identified，among which 13 showed at least 1.2 fold differences between the BPH and PCa group.Nine proteins were up-regulated and 4 proteins were down-regulated.Conclusion：A number of novel proteins associated with PCa could be identified based on iTRAQ proteomic approach，which provided new clues for the discovery of PCa biomarkers.

References:

［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2016［J］.CA Cancer J Clin，2016，66(1)：7-30.
［2］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
［3］Han Sujun，Zhang Siwei，Chen Wanqing，et al.Analysis of the status and trends of prostate cancer incidence in China［J］.Chin Clin Oncol，2013，18(4)：330-334.［韩苏军，张思维，陈万青，等.中国前列腺癌发病现状和流行趋势分析［J］.临床肿瘤杂志，2013，18(4)：330-334.］
［4］Jamaspishvili T，Kral M，Khomeriki I，et al.Urine markers in monitoring for prostate cancer［J］.Prostate Cancer Prostat Dis，2010，13(1)：12-19.
［5］Sun Chuanyu，Zhao Xiaojun，Xu Ke，et al.iTRAQ technology combined 2D LC-MS/MS differentially expressed proteins in prostate cancer screening［J］.Chin J Clinicians，2013，7(13)：5818-5822.［孙传玉，赵晓君，徐可，等.iTRAQ结合2D LC-MS/MS技术筛选前列腺癌差异表达蛋白［J］.中华临床医师杂志，2013，7(13)：5818-5822.］
［6］Chen Hanmin，Cai Lianming，Liu Lianbin，et al.The correlation between serum PSA combined PSAD and prostate diseases［J］.Modern Oncology，2014，22(7)：1640-1643.［陈汉民，蔡联明，刘联斌，等.血清PSA联合PSAD检测对前列腺癌的诊断价值［J］.现代肿瘤医学，2014，22(7)：1640-1643.］
［7］Rehman I，Evans CA，Glen A，et al.iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer［J］.PLoS One，2012，7(2)：e30885.
［8］Petricoin EF，Belluco C，Araujo RP，et al.The blood peptidome：a higher dimension of information content for cancer biomarker discovery［J］.Nat Rev Cancer，2006，6(12)：961-967.
［9］Le L，Chi K，Tyldesley S，et al.Identification of serum amyloid A as biomarker to distinguish prostate cancer patients with bone lesions［J］.Clin Chem，2005，51(4)：695-707.
［10］Byrne JC，Downes MR，O'Donoghue N，et al.2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer［J］.J Proteome Res，2009，8(2)：942-957.
［11］Sun Chuanyu，Xia Guowei，Xu Ke，et al.Application of iTRAQ in proteomic study of prostate cancer［J］.Nat J Androl，2010，16(8)：741-744.［孙传玉，夏国伟，徐可，等.iTRAQ技术在前列腺癌蛋白质组学研究中的应用［J］.中华男科学杂志，2010，16(8)：741-744.］
［12］Boichenko AP，Govorukhina N，Klip HG，et al.A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer［J］.J Proteome Res，2014，13(11)：4995-5007.
［13］Gajbhiye A，Dabhi R，Taunk K，et al.Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics［J］.Proteomics，2016，16(17)：2403-2418.
［14］Li G，Li M，Liang X，et al.Identifying DCN and HSPD1 as potential biomarkers in colon cancer using 2D-LC-MS/MS combined with iTRAQ technology［J］.Cancer，2017，8(3)：479-489.
［15］Lin C，Wu WC，Zhao GC，et al.iTRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma［J］.Medicine (Baltimore)，2016，95(31)：e4527.

Memo

Memo:
National Natural Science Foundation of China（No.81600258）；国家自然科学基金青年基金项目（编号：81600258）
Last Update: 2017-11-30